Zydus Lifesciences (NSE: ZYDUSLIFE) wins NMPA approval for Desidustat in China, unlocking access to 120 million CKD patients

Zydus Lifesciences Limited (NSE/BSE: ZYDUSLIFE), the Ahmedabad-based pharmaceutical group, has secured a significant regulatory milestone as its orally administered renal anaemia drug Desidustat received marketing approval from China’s National Medical Products Administration on March 13, 2026. The approval covers Desidustat tablets for treating anaemia in non-dialysis adult Chronic Kidney Disease patients and was granted to CMS International Development and Management Limited, a wholly-owned subsidiary of China Medical System Holdings Limited (Hong Kong: 867; Singapore: 8A8), which holds the exclusive China licence from Zydus under an agreement signed in January 2020. For Zydus Lifesciences, this marks the first time a novel chemical entity it has discovered and developed has obtained regulatory clearance in China, a market estimated to carry over 120 million CKD patients, validating both the drug’s clinical profile and the out-licensing model the company has pursued to monetise its R&D pipeline without bearing full commercialisation costs in a complex foreign market. ZYDUSLIFE shares were trading around INR 919 as of March 16, 2026, within a 52-week range of INR 795 to INR 1,059, and the stock has shed approximately 13% from its 52-week high, meaning the market has not yet priced in the full optionality from the company’s innovation pipeline.

How does Desidustat’s mechanism of action differentiate it from established CKD anaemia treatments currently available in China?

The therapeutic context matters here. CKD progressively destroys kidney function, and as kidney tissue degrades, the organ’s capacity to secrete erythropoietin falls alongside it. Reduced erythropoietin means suppressed red blood cell production, which translates into anaemia that worsens predictably through each of the five recognised disease stages. The traditional clinical response has been erythropoiesis-stimulating agents delivered via injection, a route that creates compliance challenges in non-dialysis patients who are not already attending clinical facilities on a fixed schedule. Desidustat belongs to the Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor class, a mechanistically distinct category of oral therapies. HIF-PHIs work by stabilising hypoxia-inducible factor-alpha, which in turn drives the body’s own erythropoietin production while simultaneously reducing hepcidin, the hormone that suppresses iron availability. The practical result is that the drug addresses both red blood cell production and iron metabolism in a single oral dose, without requiring injections or supervised clinical administration. This is clinically important in the non-dialysis population, where the treatment adherence gap is especially wide. Chinese data shows the target haemoglobin achievement rate in non-dialysis CKD patients with anaemia sits at only 8.2%, compared with 51.5% for haemodialysis patients, a disparity that reflects the structural barriers of injectable therapy in an ambulatory population. Desidustat’s oral route directly addresses that gap.

What does the China Phase III clinical trial data reveal about Desidustat’s efficacy and long-term safety profile?

The Phase III programme in China met its primary endpoint, which measured mean haemoglobin change from baseline through weeks seven to nine, with Desidustat demonstrating superiority over placebo in raising haemoglobin levels. The extension study data carries arguably greater commercial significance: it showed that the drug can maintain haemoglobin within target range over a sustained period with an acceptable safety profile, a standard that clinicians and regulators apply particularly strictly to non-dialysis patients given historical cardiovascular safety scrutiny across the HIF-PHI class more broadly. The trial also recorded significant reductions in hepcidin levels alongside improvements in iron metabolism, reinforcing the drug’s dual mechanism. The clinical evidence base is not built from scratch in China. Desidustat has been marketed in India under the brand name Oxemia since 2022, and Zydus reports that more than 100,000 CKD patients in India have been treated with the drug since launch. That real-world track record provides CMS with a post-approval safety dataset to support physician adoption in China beyond what the clinical trials alone could offer.

How large is the unmet need in the Chinese CKD anaemia market and what commercialisation opportunity does this create for CMS?

The scale of the patient population in China is difficult to understate in a commercial context. Estimated at more than 120 million individuals, the CKD patient base represents one of the largest single disease markets anywhere in the world. Anaemia prevalence rises sharply with disease progression, from roughly 22% at stage one CKD to nearly complete penetration at stage five. The treatment gap in non-dialysis patients, where the haemoglobin target achievement rate is still under 10%, points to a market that has not been adequately served by existing therapies rather than a market facing meaningful saturation. CMS brings an established commercialisation infrastructure to Desidustat. It already markets Velphoro, a treatment for CKD-related hyperphosphatemia, which means its nephrology sales network and physician relationships are in place. Desidustat slots into that existing clinical network as a complementary product addressing a different CKD complication, creating the potential for portfolio selling within the same specialist and institutional accounts. That kind of channel synergy reduces the commercial ramp-up cost and timeline that would otherwise face a standalone product launch.

How crowded is the HIF-PHI competitive landscape in China and where does Desidustat sit relative to rivals?

China is not unfamiliar with the HIF-PHI class. Roxadustat, developed by FibroGen and partnered with AstraZeneca for China, was the first globally approved HIF-PHI, receiving China clearance in December 2018. It has been commercially available for several years and has accumulated substantial real-world data in the Chinese market. Daprodustat, developed by GlaxoSmithKline, has also been approved in multiple markets. Several other HIF-PHIs, including vadadustat, molidustat, and enarodustat, have progressed through clinical or regulatory pathways in China and Japan. Desidustat is therefore entering a market that already has a reference class, which creates both a headwind and a strategic framing opportunity. The headwind is physician inertia around an established first-mover. The opportunity is that Desidustat arrives in the market with a defined clinical profile in the non-dialysis population and a differentiated iron metabolism story, in a segment where the aggregate market has demonstrably failed to achieve adequate treatment coverage. CMS’s commercialisation strategy will hinge on whether it can position Desidustat’s specific clinical attributes as genuinely differentiated rather than merely equivalent. In India, Zydus has had four years to build that narrative. In China, CMS is starting that work now against incumbents with established prescribing habits.

What does the out-licensing structure of the Desidustat deal mean for Zydus Lifesciences’ revenue model and innovation pipeline strategy?

The deal architecture reflects a deliberate capital-efficiency choice by Zydus Lifesciences. Rather than building a direct commercial presence in China, which would require substantial investment in a regulatory affairs organisation, local manufacturing approvals or supply partnerships, a sales force, and market access navigation through China’s National Reimbursement Drug List process, Zydus licensed the asset to CMS in 2020 and allowed the partner to carry that investment. The exact financial terms of the licensing arrangement have not been disclosed, but the commercial structure typically combines an upfront payment, development milestones, and sales-based royalties. For Zydus Lifesciences, the royalty stream from a market the size of China’s CKD population, even at modest penetration rates, could be material over a multi-year horizon. The more significant strategic signal, however, is what this approval validates about the company’s approach to novel drug discovery. Zydus has invested in building a portfolio of New Chemical Entities. Desidustat was one of the first to reach commercial approval in India, and now China has followed. For a mid-cap Indian pharmaceutical company operating at a revenue scale of approximately INR 23,500 crore in fiscal year 2025-26, demonstrating that its internally discovered molecules can clear regulatory review in both a domestic and a major international market adds a layer of credibility to its innovation story that not every Indian pharma group can claim.

What execution and market access risks could limit the commercial impact of the NMPA approval in China?

The approval is a necessary condition for commercial success, not a sufficient one. China’s reimbursement system presents the first practical obstacle. Prescription pharmaceuticals that are not included on the National Reimbursement Drug List face price barriers that limit hospital adoption and patient access in the public health system, which handles the majority of CKD patient care. Securing NRDL listing typically takes several negotiation cycles and involves price concessions that compress the commercial value of the launch. Given that roxadustat and potentially other HIF-PHIs are already on or positioned for reimbursement, Desidustat will need to demonstrate a clinical or pharmacoeconomic advantage that justifies its inclusion on terms that remain commercially viable for CMS. Beyond reimbursement, physician adoption in a class that already has established agents requires sustained medical education and clinical engagement. The non-dialysis patient segment presents particular challenges because these patients are managed across a much broader range of institutional and outpatient settings than dialysis-dependent patients, who are captured in dedicated facilities. Distribution depth rather than distribution coverage will be the commercial variable that most determines the real-world uptake trajectory.

What are the key takeaways on Desidustat’s China approval for Zydus Lifesciences, CMS, and the CKD anaemia treatment market?

• Zydus Lifesciences has achieved its first novel drug regulatory approval in China, representing a significant proof-point for the company’s New Chemical Entity strategy and validating the out-licensing model as a mechanism for international market entry without full commercialisation investment.
• The Chinese CKD patient base of over 120 million represents one of the largest addressable disease populations globally, and the treatment gap in non-dialysis patients, with haemoglobin target achievement below 10%, signals that the market is undersupplied rather than saturated.
• Desidustat’s oral administration route directly addresses the compliance challenge that limits injectable erythropoiesis-stimulating agents in non-dialysis patients, who are not attending clinical facilities on a routine schedule.
• CMS enters the launch with existing nephrology channel infrastructure through Velphoro, reducing the commercial ramp cost and enabling portfolio sales within specialist nephrology accounts.
• The HIF-PHI class is already established in China with roxadustat as the dominant reference product, and Desidustat will need to differentiate on clinical profile, particularly its iron metabolism data, or secure reimbursement positioning that gives it a formulary access advantage.
• The NMPA approval is regulatory clearance, not commercial traction. NRDL reimbursement negotiation is the next pivotal step, and the outcome of that process will have a greater bearing on real-world uptake than the approval itself.
• Over 100,000 patients treated with Desidustat in India since 2022 provides a real-world pharmacovigilance dataset that CMS can deploy in physician engagement and regulatory discussions in China, a meaningful asset for a drug entering a market with well-entrenched competitors.
• ZYDUSLIFE shares are trading approximately 13% below their 52-week high, and the market has not yet priced the royalty optionality from China into the stock, which reflects either rational caution about the commercialisation timeline or, if CMS executes well on NRDL listing, a potential re-rating catalyst as revenue contribution becomes more visible.
• For the broader Indian pharmaceutical industry, a novel drug discovered and developed domestically securing approval in both India and China sets a reference point for the sector’s ambitions beyond generics and biosimilars.
• The Zydus-CMS partnership model demonstrates that Indian drug innovators can use out-licensing not merely as a revenue mechanism but as a strategic route to global market validation without the capital outlay that direct entry into regulated markets demands.